815 results on '"targeted agents"'
Search Results
52. Effectiveness and Safety of Targeted Agents Combined With Chemoradiotherapy for the Treatment of Esophageal Cancer: A Network Meta-Analysis
- Author
-
Peng Liu, Guo-Fei Wang, Hua Peng, Lei Zhang, Xiao-Yan Li, Qiao-Miao Zeng, Qian Li, and Jian-Hui Zhou
- Subjects
esophageal cancer ,targeted agents ,chemoradiotherapy ,meta-analysis ,systematic review ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundConcurrent chemoradiotherapy (CRT) is the preferred treatment strategy for inoperable esophageal cancer (EC). However, the effect of CRT needs to be improved.MethodsThis study comprehensively analyzed targeted agents combined with CRT for the treatment of EC by a network meta-analysis. The search was performed in public databases from incipient to 5 August 2021. Randomized controlled trials comparing the effect of targeted agents combined with CRT and CRT alone on EC patients were included.ResultsTen studies were included. For progression-free survival (PFS), nivolumab (67.4%) and erlotinib (64.6%) had advantages based on Cox analysis. Regarding the frequency of PFS, cetuximab (OR: 1.39; 95% CI: 1.01, 1.91; p=0.042) and nivolumab (OR: 1.81; 95% CI: 1.34, 2.44; p
- Published
- 2021
- Full Text
- View/download PDF
53. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report.
- Author
-
Cuneo, Antonio, Rigolin, Gian Matteo, Coscia, Marta, Quaresmini, Giulia, Scarfò, Lydia, Mauro, Francesca Romana, Motta, Marina, Quaglia, Francesca Maria, Trentin, Livio, Ferrario, Andrea, Laurenti, Luca, Reda, Gianluigi, Ferrari, Angela, Pietrasanta, Daniela, Sportoletti, Paolo, Re, Francesca, De Paoli, Lorenzo, Foglietta, Myriam, Giordano, Annamaria, and Marchetti, Monia
- Subjects
COVID-19 pandemic ,CHRONIC lymphocytic leukemia - Abstract
Interestingly, the percentage of patients treated with chemo-immunotherapy (CIT) at the time of the COVID-19 infection did not change in the phase 1 (15%) compared to the phase 3 (15.7%), suggesting that this treatment modality maintained its role in a distinct minority of CLL patients. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Keywords: chronic lymphocytic leukemia; COVID-19; targeted agents; vaccination EN chronic lymphocytic leukemia COVID-19 targeted agents vaccination 570 574 5 10/08/21 20211001 NES 211001 TRANSPARENT PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1002/hon.2899. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
54. Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment.
- Author
-
Eigeliene, Natalja, Saarenheimo, Jatta, Wichmann, Viktor, Österlund, Pia, and Jekunen, Antti
- Subjects
- *
METASTASIS , *COMBINATION drug therapy , *CARCINOMA , *COMBINED modality therapy , *PREVENTIVE medicine , *DISEASE remission - Abstract
In the era of personalized medicine, systemic treatment with chemotherapy in combination with targeted drugs, tailored according to RAS and BRAF status, has improved the survival of patients with metastatic colorectal cancer (mCRC), but curative resection of metastases provides the only chance of cure. Here, we present a 40-year-old male with rectal adenocarcinoma and multiple bilateral synchronous liver metastases who has achieved long-term remission with multimodal treatment without resection of all metastatic lesions. This case emphasizes the need of repeated multidisciplinary team assessments and change of treatment intent if extraordinary responses are seen. The initial therapy consisted of short-course radiotherapy and surgery of the primary tumor followed by oxaliplatin-based combination chemotherapy and panitumumab with disease control intent. A complete radiologic response in >20 liver metastases in segments II–VIII was obtained. A biopsy-verified relapse of 3 liver metastases occurred at 9 months of treatment pause. Subsequently, major liver resection of 8 lesions was performed (4 with adenocarcinoma and 4 with cicatrix showing the challenge of disappearing lesions), followed by 6 months of adjuvant-like therapy. No relapse in MRI, PET, or CT has been noted since liver resection 6 years ago. Comprehensive genomic profiling of the primary tumor and liver metastases had similar driver mutations representing a low level of gene alteration and low diversity, possibly explaining the exceptional treatment response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
55. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
- Author
-
Subbiah, Ishwaria M, Falchook, Gerald S, Kaseb, Ahmed O, Hess, Kenneth R, Tsimberidou, Apostolia M, Fu, Siqing, Subbiah, Vivek, Hong, David S, Naing, Aung, Sarina, A Piha-Paul, Akmal, Owais, Janku, Filip, and Kurzrock, Razelle
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,Liver Disease ,Digestive Diseases ,Prevention ,Cancer ,Liver Cancer ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers ,Tumor ,Carcinoma ,Hepatocellular ,Child ,Clinical Trials ,Phase I as Topic ,Disease-Free Survival ,Female ,Humans ,Liver Neoplasms ,Male ,Middle Aged ,Molecular Targeted Therapy ,Multivariate Analysis ,Mutation ,Outcome Assessment ,Health Care ,Prognosis ,Young Adult ,targeted agents ,novel therapeutics ,management ,systemic therapy ,clinical trials ,Oncology and carcinogenesis - Abstract
PurposePatients with advanced hepatocellular carcinoma (HCC) have limited effective therapeutic options. Given the rapid advanced in drug development and emergence of novel agents, we analyzed the characteristics and outcomes of HCC patients treated on early phase trials with an emphasis on targeted therapies.MethodsWe reviewed the records of consecutive HCC patients evaluated in the Phase I Clinical Trials Program at MD Anderson from March 2004.ResultsThirty-nine patients were not treated due to poor performance status (n = 22, 56%) and decision to pursue alternate therapies (n = 10, 27%). Of 61 treated patients (median age, 60 years; median prior therapies, 3), eight patients (13%) attained stable disease lasting ≥6 months; four (7%) had a partial response, mainly with anti-angiogenic or multikinase inhibitors. Median Phase I progression-free survival (PFS) was 2.6 months versus 4.4 months (p 0.019) and 4.1 months (p 0.27) for their first-, and second-line FDA-approved therapy. Molecular analysis showed frequent PTEN loss (10/19 patients, 53%) and P53 mutation (4/4 patients tested). On multivariate analysis, independent factors predicting shorter survival were white ethnicity/race (p 0.031), cirrhosis (p 0.016), and serum sodium (p 0.0013).ConclusionsIn our heavily-pretreated HCC patients, the phase I PFS was comparable to that of 2nd-line therapy, highlighting a potential role for clinical trials after progression on first-line therapy. The response rate (SD>6 months/PR) of 20% was observed with early signals of activity in regimens combining inhibitors of angiogenesis, multiple kinases and mTOR with preliminary molecular analysis revealing prevalence of PTEN loss.
- Published
- 2015
56. Therapy: Recommendations for the Oncologists
- Author
-
Facchinetti, Francesco, Gnetti, Letizia, Tiseo, Marcello, Giordano, Antonio, Series Editor, Franco, Renato, editor, and Zito Marino, Federica, editor
- Published
- 2018
- Full Text
- View/download PDF
57. Thymic Neoplasm
- Author
-
Marino, Mirella, Facciolo, Francesco, Shen, Yan, Alessandrini, Gabriele, Girard, Nicolas, Giordano, Antonio, Series Editor, Franco, Renato, editor, and Zito Marino, Federica, editor
- Published
- 2018
- Full Text
- View/download PDF
58. New Data on Systemic Therapy of Salivary Gland Tumors
- Author
-
Alfieri, Salvatore, Licitra, Lisa, Vermorken, Jan B., editor, Budach, Volker, editor, Leemans, C. René, editor, Machiels, Jean-Pascal, editor, Nicolai, Piero, editor, and O'Sullivan, Brian, editor
- Published
- 2018
- Full Text
- View/download PDF
59. Breast Cancer
- Author
-
Lambertini, Matteo, Aftimos, Philippe, Gombos, Andrea, Awada, Ahmad, Piccart, Martine, Dicato, Mario A., editor, and Van Cutsem, Eric, editor
- Published
- 2018
- Full Text
- View/download PDF
60. Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Author
-
Robert, Caroline, Mateus, Christina, Eggermont, Alexander M. M., Dicato, Mario A., editor, and Van Cutsem, Eric, editor
- Published
- 2018
- Full Text
- View/download PDF
61. Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials
- Author
-
Pang Y, Shen Z, Sun J, and Wang W
- Subjects
targeted agents ,gastro-esophageal cancer ,complete response ,randomized controlled trials ,meta-analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Yanyang Pang,1 Zhen Shen,2 Jiancheng Sun,3 Wu Wang4 1Department of Traditional Chinese Medicine, Hainan Medical University, Haikou, Hainan 571101, China; 2Division of Liver Disease, Huangshi City Hospital of Traditional Chinese Medicine (Infectious Disease Hospital), Edong Healthcare Group, Huangshi, Hubei 435000, China; 3Department of General Surgery, The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; 4Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, Hainan 571101, China Purpose: We aimed to investigate whether the use of targeted agents (TAs) in advanced gastroesophageal cancer (GEC) increased the complete response (CR) and to assess the surrogate endpoints for survival in the targeted treatment of GEC by using a meta-analysis of randomized controlled trials (RCTs).Methods: Eligible studies were identified using Medline, PubMed, and meeting abstracts. Searches were last updated on April 30, 2018. We calculated the incidence and Peto odds ratio (Peto OR) of CR events in patients assigned to TAs compared with controls. Simple linear regression models were fitted for median overall survival (OS) and each surrogate [median progression-free survival (PFS), CRs, objective response rate (ORR), and disease control rate (DCR), respectively].Results: A total of 7,892 GEC patients from 18 RCTs were included for analysis. The incidence of CR in GEC patients treated with TAs was 2.0% (95% CI, 1.3%–3.0%) compared with 1.7% (95% CI, 1.0%–2.7%) in the control arms. The use of TAs in advanced GEC had a tendency to improve the possibility of archiving CR (Peto OR 1.42; 95% CI, 0.98–2.04; P=0.064) compared with controls. Subgroup analysis according to treatment TAs showed that the addition of antiepidermal growth factor receptor (EGFR) agents to chemotherapy in GEC significantly improved the CR rate in comparison with control (Peto OR 1.77; 95% CI, 1.02–3.09; P=0.044), but not for other molecular TAs (P=0.49 for angiogenesis inhibitors, P=0.66 for mesenchymal-epithelial transition inhibitors). We also found that the addition of TAs to first-line therapy (Peto OR 1.41; 95% CI, 0.94–2.11; P=0.098) had a tendency to increase the chance of obtaining a CR, but not for second-line therapy (Peto OR 1.47; 95% CI, 0.60–3.55; P=0.40). In addition, correlation analysis indicates that PFS, ORR, and DCR were strongly correlated with OS for GEC patients receiving TAs (r=0.85 for PFS; r=0.86 for ORR; r=0.81 for DCR). No marked correlation was found between OS and CRs (r=0.43; P=0.18).Conclusion: Although the CR is a rate event in advanced GEC patients, adding the TAs to therapies, especially for anti-EGFR agents, increases the chance of archiving CR in comparison with the controls. PFS, ORR, and DCR are significantly correlated with OS and could be used as surrogate endpoints in patients with GEC who have received TA therapy, but not for CR. Keywords: gastroesophageal carcinoma, systematic review, novel molecular agents
- Published
- 2018
62. Current Therapies and Future Directions in Treatment of Glioblastoma
- Author
-
Wang, Joshua L., Mugge, Luke, Giglio, Pierre, Puduvalli, Vinay K., El-Deiry, Wafik, Series editor, and Somasundaram, Kumaravel, editor
- Published
- 2017
- Full Text
- View/download PDF
63. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
- Author
-
Spetsieris, Nicholas, Boukovala, Myrto, Weldon, Justin A., Tsikkinis, Alexandros, Anh Hoang, Aparicio, Ana, Shi-Ming Tu, Araujo, John C., Zurita, Amado J., Corn, Paul G., Pagliaro, Lance, Kim, Jeri, Wang, Jennifer, Subudhi, Sumit K., Tannir, Nizar M., Logothetis, Christopher J., Troncoso, Patricia, Xuemei Wang, Sijin Wen, and Efstathiou, Eleni
- Subjects
- *
CLINICAL trials , *ABIRATERONE acetate , *DASATINIB , *SUNITINIB , *CASTRATION-resistant prostate cancer - Abstract
The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. In an open-label randomized phase 2 study, no difference was reported in overall survival or time to treatment failure between dasatinib and sunitinib combined with abiraterone after disease progression while receiving abiraterone monotherapy in patients with bone metastatic castration-resistant prostate cancer. Background: Resistance to novel androgen signaling inhibition and metastatic castration-resistant prostate cancer (mCRPC) progression is likely dependent on tumor microenvironment interactions. The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. We studied the effect of adding the targeted agents dasatinib and sunitinib to abiraterone acetate (AA) in men with mCRPC. Patients and Methods: In this open-label randomized phase 2 study, mCRPC patients received AA. At resistance to AA, they were randomized 1:1 to combination with dasatinib or sunitinib. At second progression, patients crossed over. The primary end point was time to treatment failure (TTF), defined as time to progression or death. Secondary end points included overall survival and safety. Results: From March 2011 to February 2015, a total of 179 patients were enrolled and 132 subsequently randomized. Median TTF was 5.7 months in the dasatinib group and 5.5 months in the sunitinib group. There was no difference between the two groups in terms of TTF (hazard ratio, 0.85; 95% confidence interval, 0.59-1.22). Median overall survival from study entry was 26.3 months in the dasatinib group and 27.7 months in the sunitinib group (hazard ratio, 1.02; 95% confidence interval, 0.71-1.47). Grade 3 or higher adverse events related to study medication were more frequent with sunitinib (n = 44, 46%) compared to dasatinib (n = 26, 24%). At data cutoff, 7 patients were experiencing a continuous response to AA, with a median duration of treatment of 5.7 years. Conclusion: There is no difference in overall survival and TTF between dasatinib and sunitinib combined with abiraterone in the treatment of patients with bone mCRPC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
64. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.
- Author
-
Arend, Rebecca C., Jackson-Fisher, Amy, Jacobs, Ira A., Chou, Jeffrey, and Monk, Bradley J.
- Subjects
- *
VASCULAR endothelial growth factor receptors , *POLY ADP ribose , *OVARIAN cancer , *AGROBACTERIUM tumefaciens - Abstract
Recently approved therapies have contributed to a significant progress in the management of ovarian cancer; yet, more options are needed to further improve outcomes in patients with advanced disease. Here we review the rationale and ongoing clinical trials of novel combination strategies involving chemotherapy, poly ADP ribose polymerase, programmed death 1 (PD-1)/PD-ligand 1 immune checkpoint and/or vascular endothelial growth factor receptor inhibitors. Further, we discuss novel agents aimed at targets associated with ovarian cancer growth or progression that are emerging as potential new treatment approaches. Among them, agents targeted to folate receptor α, tissue factor, and protein kinase-mediated pathways (WEE1 kinase, phosphatidylinositol-3 kinase α, cell cycle checkpoint kinase 1/2, ATR kinase) are currently in clinical development as mono- or combination therapies. If successful, findings from these extensive development efforts may further transform treatment of patients with advanced ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
65. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas [version 1; peer review: 3 approved]
- Author
-
Cheryl Foster and John Kuruvilla
- Subjects
Review ,Articles ,T-cell lymphoma ,relapsed ,refractory ,stem cell transplant ,targeted agents - Abstract
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare and aggressive non-Hodgkin’s lymphomas. Clinical staging, prognostic scoring, and initial treatment strategies have historically been based on paradigms developed in B-cell lymphomas. Despite primary treatment protocols that are typically anthracycline-based and frequently involve consolidative autologous stem cell transplantation in first remission, many patients develop disease progression. There remains a high unmet medical need for improved treatment strategies in the relapsed or refractory setting. Salvage chemotherapy and stem cell transplantation in those who are suitable has traditionally been the accepted approach, but this remains a minority of the total patient population. As increasing knowledge is gleaned regarding the biological heterogeneity within the various PTCL subtypes, newer targeted agents have been developed, studied, and approved in this small, heterogeneous population of relapsed or refractory disease. Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL. As others undergo further development in the relapsed setting and successes are brought earlier in the disease course, the outcome for PTCL patients is likely to improve. However, innovative clinical trial designs are crucial for the assessment of targeted agents in this highly heterogeneous population. This review explores the current treatment environment for patients with relapsed and refractory PTCL, including newer strategies such as targeted agents and immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF
66. Editorial: Next-Generation Cancer Therapies Based on a (R)evolution of the Biomarker Landscape.
- Author
-
Cerella, Claudia, Lorant, Anne, Aquilano, Katia, and Diederich, Marc
- Subjects
CANCER treatment ,BIOMARKERS ,TUMOR markers ,TREATMENT effectiveness ,NUCLEOTIDE sequencing - Published
- 2022
- Full Text
- View/download PDF
67. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
- Author
-
Arber, Daniel A and Erba, Harry P
- Subjects
- *
ACUTE myeloid leukemia , *MOLECULAR pathology , *MYELOID leukemia , *THERAPEUTIC use of antineoplastic agents , *MYELODYSPLASTIC syndromes , *ONLINE information services , *RESEARCH , *SEQUENCE analysis , *HETEROCYCLIC compounds , *RESEARCH methodology , *PROGNOSIS , *EVALUATION research , *MEDICAL cooperation , *BLOOD cells , *COMPARATIVE studies , *AMINOPYRIDINES , *DISEASE susceptibility , *CHROMOSOME abnormalities , *MEDLINE , *DAUNOMYCIN , *CYTARABINE , *CYTOGENETICS , *BONE marrow ,BONE marrow examination - Abstract
Objectives: Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) represents a high-risk and somewhat diverse subtype of AML, and substantial confusion exists about the pathologic evaluation needed for diagnosis, which can include the patient's clinical history, cytogenetic analysis, mutational analysis, and/or morphologic evaluation. Treatment decisions based on incomplete or untimely pathology reports may result in the suboptimal treatment of patients with AML-MRC.Methods: Using a PubMed search, diagnosis of and treatment options for AML-MRC were investigated.Results: This article reviews the current diagnostic criteria for AML-MRC, provides guidance on assessments necessary for an AML-MRC diagnosis, summarizes clinical and prognostic features of AML-MRC, and discusses potential therapies for patients with AML-MRC. In addition to conventional chemotherapy, treatment options include CPX-351, a liposomal encapsulation of daunorubicin/cytarabine approved for treatment of adults with AML-MRC; targeted agents for patients with certain mutations/disease characteristics; and lower-intensity therapies for less fit patients.Conclusions: Given the evolving and complex treatment landscape and the high-risk nature of the AML-MRC population, a clear understanding of the pathology information necessary for AML-MRC diagnosis has become increasingly important to help guide treatment decisions and thereby improve patient outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
68. Molecular Biomarkers: A review of multiple applications in clinical care of colorectal cancer.
- Author
-
Schmitt, Mary L.
- Subjects
- *
COLON tumor prevention , *BIOMARKERS , *CELLULAR signal transduction , *COLON tumors , *DEGENERATION (Pathology) , *DNA , *IMMUNOHISTOCHEMISTRY , *GENETIC mutation , *ONCOGENES , *POLYMERASE chain reaction , *PROGNOSIS , *TUMOR markers , *WORLD Wide Web , *GENETIC testing , *GENOMICS , *CONTINUING education units , *INDIVIDUALIZED medicine , *EPIDERMAL growth factor receptors , *GENE expression profiling ,TUMOR prevention ,RECTUM tumors - Abstract
BACKGROUND: Advancements in tumor profiling have identified multiple molecular biomarkers that influence tumor growth and behavior. Molecular biomarkers provide clinical prognostic and predictive information, which guides treatment decisions and forms the backbone of precision oncology. OBJECTIVES: This article identifies key predictive and prognostic molecular biomarkers used in the treatment of colorectal cancer and provides greater understanding of their biologic significance and usefulness in guiding treatment decisions. METHODS: A review of the literature and professional guidelines was performed to evaluate approved molecular biomarkers, targeted agents, and tumor testing modalities used for the management and treatment of colorectal cancer, with an emphasis on treatment decision making. FINDINGS: Genomic biomarkers are increasingly used for the prevention, diagnosis, prognostication, and management of colorectal cancer. The introduction of targeted agents and advancements in tumor profiling technologies have increased treatment opportunities and improved clinical outcomes for patients with colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
69. Lymphomes T périphériques : diagnostic et prise en charge.
- Author
-
Galtier, J., Parrens, M., and Milpied, N.
- Subjects
- *
T cells , *LYMPHOMAS , *IMMUNE system , *CANCER chemotherapy - Abstract
Peripheral T cell lymphomas are rare malignancies with aggressive course, with several different subtype described in the 2016 WHO classification. Their distribution across the world is heterogenous, with marked difference between Western and Asian country. Their clinical presentation often comprise extra-nodal involvement, B symptoms and immune system disorder which can lead to wrong diagnosis orientation. Make a right diagnosis need a experienced pathologist in close collaboration with clinical datas. Peripheral T cell lymphomas are in general associated with poor prognosis when treated with anthracyclines-based regimen, and several studies and trials focused on the use of intensified regimen or novel targeted agents, whose proper indication still remain to be clarified. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
70. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data.
- Author
-
ZHILI ZENG, ZEBIAO CAO, and YING TANG
- Subjects
- *
HEPATITIS B , *HEPATOCELLULAR carcinoma , *CHRONIC hepatitis B , *GENE expression profiling , *BIOMARKERS , *HEPATITIS B virus - Abstract
Primary liver cancer is a rapidly progressing neoplasm with high morbidity and mortality rates. The present study aimed to identify potential diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus (HBV)-associated early stage hepatocellular carcinoma (HCC). The gene expression profiles were extracted from the Gene Expression Omnibus database. Differentially expressed genes (DEGs), hub genes and the enrichment of signaling pathways were filtered out via a high-throughput sequencing method. The association between hub genes and the effects of the abnormal expression of hub genes on the rate of genetic variation, overall survival (OS), relapse-free survival (RFS), progression-free survival (PFS) and disease-free survival (DSS) of patients with HCC, as well as pathological stage and grade, were analyzed using different databases. A total of 1,582 DEGs were identified. Gene Ontology analysis revealed that the DEGs were mainly involved in the 'oxidation-reduction process', 'steroid metabolic process', 'metabolic process' and 'fatty acid beta-oxidation'. Enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways revealed that the DEGs were mainly associated with 'metabolic pathways', 'PPAR signaling pathway', 'fatty acid degradation' and the 'cell cycle'. A total of 8 hub genes were extracted. Additionally, the abnormal expression levels of hub genes were closely associated with the OS, RFS, PFS and DSS of patients, the pathological stage and the grade. Furthermore, abnormal expression levels of the 8 hub genes were found in >30% of all samples. Several small molecular compounds that may reverse the altered DEGs were identified based on Connectivity Map analysis, including phenoxybenzamine, GW-8510, resveratrol, 0175029-0000 and daunorubicin. In conclusion, the dysfunction of fat metabolic pathways, the cell cycle, oxidation-reduction processes and viral carcinogenesis may serve critical roles in the occurrence of HBV-associated early stage HCC. The identified 8 hub genes may act as robust biomarkers for diagnosis and prognosis. Some small molecular compounds may be promising targeted agents against HBV-associated early stage HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
71. Nanoparticle contrast agents for X‐ray imaging applications.
- Author
-
Hsu, Jessica C., Nieves, Lenitza M., Betzer, Oshra, Sadan, Tamar, Noël, Peter B., Popovtzer, Rachela, and Cormode, David P.
- Abstract
X‐ray imaging is the most widely used diagnostic imaging method in modern medicine and several advanced forms of this technology have recently emerged. Iodinated molecules and barium sulfate suspensions are clinically approved X‐ray contrast agents and are widely used. However, these existing contrast agents provide limited information, are suboptimal for new X‐ray imaging techniques and are developing safety concerns. Thus, over the past 15 years, there has been a rapid growth in the development of nanoparticles as X‐ray contrast agents. Nanoparticles have several desirable features such as high contrast payloads, the potential for long circulation times, and tunable physicochemical properties. Nanoparticles have also been used in a range of biomedical applications such as disease treatment, targeted imaging, and cell tracking. In this review, we discuss the principles behind X‐ray contrast generation and introduce new types of X‐ray imaging modalities, as well as potential elements and chemical compositions that are suitable for novel contrast agent development. We focus on the progress in nanoparticle X‐ray contrast agents developed to be renally clearable, long circulating, theranostic, targeted, or for cell tracking. We feature agents that are used in conjunction with the newly developed multi‐energy computed tomography and mammographic imaging technologies. Finally, we offer perspectives on current limitations and emerging research topics as well as expectations for the future development of the field. This article is categorized under:Diagnostic Tools > in vivo Nanodiagnostics and ImagingNanotechnology Approaches to Biology > Nanoscale Systems in Biology [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
72. A Review of Nanotechnology for Targeted Anti-schistosomal Therapy
- Author
-
Tayo Alex Adekiya, Pierre P. D. Kondiah, Yahya E. Choonara, Pradeep Kumar, and Viness Pillay
- Subjects
schistosomiasis ,nanoparticles ,drug delivery ,targeted agents ,molecular receptors ,antibody ,Biotechnology ,TP248.13-248.65 - Abstract
Schistosomiasis is one of the major parasitic diseases and second most prevalent among the group of neglected diseases. The prevalence of schistosomiasis may be due to environmental and socio-economic factors, as well as the unavailability of vaccines for schistosomiasis. To date, current treatment; mainly the drug praziquantel (PZQ), has not been effective in treating the early forms of schistosome species. The development of drug resistance has been documented in several regions globally, due to the overuse of PZQ, rate of parasitic mutation, poor treatment compliance, co-infection with different strains of schistosomes and the overall parasite load. Hence, exploring the schistosome tegument may be a potential focus for the design and development of targeted anti-schistosomal therapy, with higher bioavailability as molecular targets using nanotechnology. This review aims to provide a concise incursion on the use of various advance approaches to achieve targeted anti-schistosomal therapy, mainly through the use of nano-enabled drug delivery systems. It also assimilates the molecular structure and function of the schistosome tegument and highlights the potential molecular targets found on the tegument, for effective specific interaction with receptors for more efficacious anti-schistosomal therapy.
- Published
- 2020
- Full Text
- View/download PDF
73. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
- Author
-
Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, and Lou L
- Subjects
hepatocellular cancer ,fatal adverse events ,randomized controlled trials ,meta-analysis ,targeted agents ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Xiaofei Li,1 Jia Wan,2 Zhenping Wu,3 Juncai Tu,1 Yongtao Hu,1 Shuang Wu,1 Lianqing Lou1 1Department of Infectious Diseases, Yiwu Central Hospital, Yiwu, China; 2The First Hospital of Nanchang, Nanchang, China; 3Gastroenterology Department, Jinhua Central Hospital, Jinhua, China Aims: Concerns have increased about the risk of fatal adverse events (FAEs) associated with molecular targeted agents (MTAs) in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study is to investigate the overall incidence and risk of FAEs in advanced HCC with administration of MTAs by using a meta-analysis of available clinical trials.Materials and methods: Electronic databases were searched for relevant articles before March 2017. Eligible studies were selected according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Pooled incidence, Peto ORs and 95% CIs were calculated according to the heterogeneity of selected studies.Results: A total of 4,716 HCC participants from 10 randomized controlled trials (RCTs) were finally considered for this meta-analysis. The pooled incidence of death due to MTAs was 2.1% (95% CI 1.6%–2.8%) with a Peto OR of 1.79 (95% CI 1.07–3.01; p=0.027) in comparison with controlled groups. Subgroup analysis according to biological agents showed that brivanib treatment in HCC patients significantly increased the risk of developing FAEs (Peto OR 3.97; 95% CI 1.17–13.51; p=0.028) but not for sorafenib (Peto OR 1.78; 95% CI 0.54–5.89; p=0.34) and other MTAs (Peto OR 1.43; 95% CI 0.75–2.76; p=0.28). Sensitive analysis showed that the pooled results were influenced by removing each single trial. The most common causes of FAEs were hepatic failure (22.2%) and hemorrhage (13.3%), respectively.Conclusion: Clinicians should be aware of the risks of FAEs during the administration of MTAs in advanced HCC patients, especially for patients with abnormal liver function. However, the use of sorafenib remains justified in its approved indications due to their potential survival benefits and limited toxicities. Keywords: liver cancer, clinical trials, novel molecular agents
- Published
- 2018
74. The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta‐analysis
- Author
-
Xi Zhong, Zhonghua Wu, Peng Gao, Jinxin Shi, Jingxu Sun, Zhexu Guo, Zhenning Wang, and Yongxi Song
- Subjects
Efficacy ,neoadjuvant therapy ,pathologic complete response ,rectal cancer ,targeted agents ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Patients with locally advanced rectal cancer (LARC) are at tremendous risk of metastatic diseases. To improve the prognoses of LARC patients, the efficacy of adding targeted agents to neoadjuvant therapy has been investigated by many researchers but remains controversial. A literature search of relevant databases was conducted through December 2016, 804 studies were identified and 32 investigations were ultimately included. A total of 1196 patients from 31 cohorts of 29 studies were eligible for quantitative synthesis in this single‐arm setting meta‐analysis. As pathologic complete response (pCR) shows promise as a prognosis indicator, we focused on pCR rates to evaluate whether adding targeted agents to neoadjuvant therapies improves the outcome of LARC patients. In our study, we revealed pooled estimates of pCR of 27% (95%CI, 21–34%) and 14% (95%CI, 9–21%) for bevacizumab‐relevant cohorts and cetuximab‐relevant cohorts, respectively. The safety of adding targeted agents to neoadjuvant therapy was also evaluated by pooling the data of Grade 3/4 toxicity. In conclusion, our study revealed that adding bevacizumab to the neoadjuvant therapy regimens provides appreciable pCR for LARC patients. Meanwhile, the efficacy of cetuximab remains inconclusive, RCTs with larger scale and better study design that stress more on mutational status are needed.
- Published
- 2018
- Full Text
- View/download PDF
75. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials
- Author
-
Jin JM, Teng CB, and Li T
- Subjects
pancreatic cancer ,elderly ,randomized controlled trials ,meta-analysis ,targeted agents ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Jiamin Jin, Chunbo Teng, Tao Li College of Life Science, Northeast Forestry University, Harbin, China Purpose: We aimed to compare the efficacy of combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer (PC) by using a meta-analysis.Materials and methods: Databases were searched to identify relevant clinical trials. Hazard ratios (HRs) were used to estimate overall survival (OS) and progression-free survival (PFS). Statistical analyses were conducted by using Comprehensive Meta Analysis software (version 2.0).Results: A total of 3,401 elderly PC patients from six randomized controlled trials were included for analysis. In comparison with gemcitabine alone, combination therapy in elderly PC patients did not significantly improve OS (HR 0.93, 95% CI: 0.82–1.06, p=0.29). Sub-group analysis according to treatment regimens showed that combined chemotherapy significantly improved OS in comparison with gemcitabine alone (HR 0.73, 95% CI: 0.56–0.94, p=0.016), while gemcitabine plus targeted agents did not improve OS (HR 1.02, 95% CI: 0.87–1.19, p=0.83). Additionally, gemcitabine plus nab-paclitaxel significantly improved PFS in elderly PC patients (HR 0.69, 95% CI: 0.52–0.91, p=0.009) in comparison with gemcitabine alone. No publication bias was detected by Begg’s and Egger’s tests for OS.Conclusion: The findings of this study suggest that combined chemotherapy, but not for gemcitabine plus targeted agents, could be recommended for elderly PC patients due to its survival benefits. Further studies are still needed to assess the treatment tolerance of combination chemotherapy in these patient populations. Keywords: pancreatic cancer, elderly, randomized controlled trials, meta-analysis, targeted agents
- Published
- 2018
76. Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents
- Author
-
Gail M Wilkes
- Subjects
Cancer ,immunological ,molecular ,targeted agents ,targeted therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Nursing ,RT1-120 - Abstract
Today, personalized cancer therapy with targeted agents has taken center stage, and offers individualized treatment to many. As the mysteries of the genes in a cell's DNA and their specific proteins are defined, advances in the understanding of cancer gene mutations and how cancer evades the immune system have been made. This article provides a basic and simplified understanding of the available (Food and Drug Administration- approved) molecularly and immunologically targeted agents in the USA. Other agents may be available in Asia, and throughout the USA and the world, many more agents are being studied. Nursing implications for drug classes are reviewed.
- Published
- 2018
- Full Text
- View/download PDF
77. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
- Author
-
Mehta, Minesh P, Paleologos, Nina A, Mikkelsen, Tom, Robinson, Paula D, Ammirati, Mario, Andrews, David W, Asher, Anthony L, Burri, Stuart H, Cobbs, Charles S, Gaspar, Laurie E, Kondziolka, Douglas, Linskey, Mark E, Loeffler, Jay S, McDermott, Michael, Olson, Jeffrey J, Patchell, Roy A, Ryken, Timothy C, and Kalkanis, Steven N
- Subjects
Cancer ,Brain Disorders ,Neurosciences ,Rare Diseases ,Lung ,Lung Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Brain Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Brain Neoplasms ,Drug Therapy ,Evidence-Based Medicine ,Humans ,Practice Guidelines as Topic ,Brain metastases ,Chemotherapy ,Whole brain radiation therapy ,Targeted agents ,Systematic review ,Practice guideline ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Target populationThis recommendation applies to adults with newly diagnosed brain metastases; however, the recommendation below does not apply to the exquisitely chemosensitive tumors, such as germinomas metastatic to the brain.RecommendationShould patients with brain metastases receive chemotherapy in addition to whole brain radiotherapy (WBRT)? Level 1 Routine use of chemotherapy following WBRT for brain metastases has not been shown to increase survival and is not recommended. Four class I studies examined the role of carboplatin, chloroethylnitrosoureas, tegafur and temozolomide, and all resulted in no survival benefit. Two caveats are provided in order to allow the treating physician to individualize decision-making: First, the majority of the data are limited to non small cell lung (NSCLC) and breast cancer; therefore, in other tumor histologies, the possibility of clinical benefit cannot be absolutely ruled out. Second, the addition of chemotherapy to WBRT improved response rates in some, but not all trials; response rate was not the primary endpoint in most of these trials and end-point assessment was non-centralized, non-blinded, and post-hoc. Enrollment in chemotherapy-related clinical trials is encouraged.
- Published
- 2010
78. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
- Author
-
Taghizadeh, Hossein, Müllauer, Leonhard, Mader, Robert M., Schindl, Martin, and Prager, Gerald W.
- Abstract
Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) bears a dismal prognosis due to the limited activity of systemic chemotherapy. In our platform for precision medicine, we aim to offer molecular-guided treatments to patients without further standard therapy options. Methods: In this single center, real-world retrospective analysis of our platform, we describe the molecular-based therapy approaches used in all 50 patients diagnosed with therapy-refractory mPDAC. A molecular portrait of the tumor specimens was created by next-generation sequencing, immunohistochemistry (IHC), microsatellite instability (MSI) testing, and fluorescence in situ hybridization. Results: In total, we detected 123 mutations in 50 patients. The five most frequent mutations were KRAS (n = 40; 80%), TP53 (n = 29; 58%), CDKN2A (n = 8; 16%), SMAD4 (n = 4; 8%), and NOTCH1 (n = 4; 8%), which together accounted for 40.2% of all mutations. Two patients had gene fusions, namely, TBL1XR1–PIK3CA and EIF3E–RSPO2. IHC detected expression of EGFR, phosphorylated mTOR, and PTEN in 36 (72%), 33 (66%), and 17 patients (34%), respectively. For 14 (28%) of the 50 patients, a targeted therapy was suggested based on the identified molecular targets. The recommended treatments included the mTOR inhibitor everolimus (n = 3), pembrolizumab (n = 3), palbociclib (n = 2), nintedanib (n = 2), and cetuximab, crizotinib, tamoxifen, and the combination of lapatinib and trastuzumab, in one patient each. Finally, five patients received the recommended therapy. Four patients died due to disease progression before radiological assessment. One patient was treated with nintedanib and achieved stable disease for 6 months. Conclusion: Based on our observations, precision medicine approaches are feasible and implementable in clinical routine and may provide molecular-based therapy recommendations for mPDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
79. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform.
- Author
-
Taghizadeh, Hossein, Mader, Robert M., Müllauer, Leonhard, Aust, Stefanie, Polterauer, Stephan, Kölbl, Heinz, Seebacher, Veronika, Grimm, Christoph, Reinthaller, Alexander, and Prager, Gerald W.
- Subjects
BIOMARKERS ,COLLECTION & preservation of biological specimens ,FEMALE reproductive organ tumors ,HEALTH care teams ,IMMUNOHISTOCHEMISTRY ,MOLECULAR diagnosis ,MOLECULAR pathology ,PHOSPHORYLATION ,TUMOR classification ,GENETIC markers ,RETROSPECTIVE studies ,INDIVIDUALIZED medicine ,DESCRIPTIVE statistics - Abstract
Introduction: Advanced gynecologic cancers have a poor prognosis and constitute a major challenge for adequate treatment strategies. By analyzing and targeting molecular alterations, molecular guided treatments may be a viable option for the treatment of advanced gynecologic cancers. Patients and Methods: In this single‐center, real‐world retrospective analysis of our platform for precision cancer medicine (PCM), we describe the molecular profiling of 72 patients diagnosed with different types of advanced gynecologic malignancies. Tumor samples of the patients were examined by next‐generation sequencing panel and immunohistochemistry (IHC). Results: In total, we identified 209 genetic aberrations in 72 patients. The ten most frequent alterations were TP53 (n = 42, 20%), KRAS (n = 14, 6.6%), PIK3CA (n = 11, 5.2%), PIK3R1 (n = 9, 4.3%), ATR (n = 8, 3.8%), PTEN (n = 8, 3.8%), BRCA1 (n = 6, 2.8%), NF1 (n = 4, 1.9%), NOTCH1 (n = 4, 1.9%), and POLE (n = 4, 1.9%), which account for more than half of all molecular alterations (52.6%). In 21 (29.1%) patients only one mutation could be detected, and 44 (61.1%) patients had more than one mutation. No molecular alterations were detected in seven (9.7%) patients. IHC detected expression of phosphorylated mammalian target of rapamycin and epidermal growth factor receptor in 58 (80.6%) and 53 (73.6%) patients, respectively. In over two thirds (n = 49, 68.1%), a targeted therapy was suggested, based on the identified genetic aberrations. The most frequently recommended specific treatment was the combination of everolimus with exemestane (n = 18, 25 %). Conclusion: Based on our observations, it seems that PCM might be a feasible approach for advanced gynecologic cancers with limited treatment options. Implications for Practice: Nowadays molecular profiling of advanced gynecologic malignancies is feasible in the clinical routine. A molecular portrait should be done for every patient with an advanced therapy‐refractory gynecologic malignancy to offer molecular‐based treatment concepts. To determine the feasibility of precision cancer medicine (PCM) in gynecologic cancers, this retrospective study analyzed patients with advanced gynecologic cancers enrolled and profiled in a PCM platform, MONDTI, focusing on the technical feasibility to map the molecular profiles of advanced, pretreated, and mainly relapsed gynecologic cancers and to subsequently target the detected molecular alterations [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
80. Bladder cancer genomics.
- Author
-
Siracusano, Salvatore, Rizzetto, Riccardo, and Porcaro, Antonio Benito
- Subjects
- *
BLADDER cancer , *MOLECULAR pathology , *GENETIC load , *POLYMERASE chain reaction , *GENE expression - Abstract
Until recently, the treatment of bladder cancer, for several years, was limited to surgery and to immunotherapy or chemotherapy. Currently, the extensive analysis of molecular alterations has led to novel treatment approaches. The advent of polymerase chain reaction and genomic hybridization techniques has allowed to investigate alterations involved in bladder cancer at DNA level. By this way, bladder cancers can be classified as papillary or non-papillary based on genetic alterations with activation or mutations in FGFR3 papillary tumors and with inactivation or mutations involving TP53 and RB1 in non-papillary tumors. Recently, the patterns of gene expression allow to differentiate basal and luminal subtypes as reported in breast cancer. In particular, basal cancers are composed of squamous and sarcomatoid pathological findings, while luminal cancers are composed of papillary finding features and genetic mutations (FGFR3). In particular, specific investigative studies demonstrated that luminal cancers are associated with secondary muscle invasive cancer while basal tumors are related to advanced disease since they are often metastatic at diagnosis. Moreover, from therapeutic point of view, different researchers showed that mutations of DNA are related to the sensitivity of bladder cancer while performing cisplatin chemotherapy. In this prospective, the bladder cancer molecular subtyping classification might allow identifying the set of patients who can safely avoid neoadjuvant chemotherapy likely because of the low response to systemic chemotherapy (chemoresistant tumors). In this context, the Cancer Genome Atlas (TCGA) project has improved the knowledge of the molecular targets of invasive urothelial cancers allowing the researchers to propose hypothesis suggesting that agents targeting the genomic alterations may be an effective strategy in managing these cancers, which occur in about 68% of muscle invasive cancers. A future goal will be to combine treatment strategies of invasive bladder cancers according to their genetic mutational load defined by molecular pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
81. Prevention of relapse after allogeneic stem cell transplantation in acute myeloid leukemia: Updates and challenges.
- Author
-
Thekkudan, Shinto F., Lima, Marcos, and Metheny, Leland
- Subjects
- *
ACUTE myeloid leukemia treatment , *STEM cell transplantation , *CANCER relapse - Abstract
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative treatment for acute myeloid leukemia (AML). Reduced intensity regimens, alternative graft sources, advances in HLA‐matching, improved supportive care, and tailored graft versus host disease (GVHD) prophylaxis have led to a wider application of allo‐HSCT to eligible patients. Unfortunately, 30‐40% of patients with AML will relapse after transplant and this is the major cause of treatment failure. Careful consideration should be paid in choosing the type of graft, graft source, and conditioning regimen to minimize the risk of disease recurrence. In addition, maintenance therapy following allo‐HSCT is a potential method to keep the disease in remission, especially in those with high‐risk disease characteristics. Pharmacological targeted agents with low side effect profile such as tyrosine kinase inhibitors, hypomethylating agents (HMAs), HDAC inhibitors, antibody drug conjugates (ADCs), isocitrate dehydrogenase inhibitors, and hedgehog inhibitors may prevent relapse in posttransplant setting and are under investigation. Immunological therapies including donor lymphocyte infusions (DLIs), natural killer (NK) cell therapy, peptide vaccine targeting tumor antigens, and adoptive T‐cell therapies all hold promises in this area as well. As targeted agents and immunotherapies continue to be developed, patients at high risk of recurrence may benefit from prophylactic maintenance therapy. Here we review the current landscape in this rapidly evolving clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
82. Targeted therapy for breast cancer in older patients.
- Author
-
Pondé, Noam, Wildiers, Hans, Awada, Ahmad, de Azambuja, Evandro, Deliens, Coralie, and Lago, Lissandra Dal
- Abstract
Older patients are one of the most relevant sub-groups of patients with breast cancer and will only gain in importance as demographic transition unfolds. Their management, in both the early and advanced settings, should take into consideration specific clinical needs and is made more difficult by the limited availability of evidence on the efficacy and safety of standard treatment regimens in older patients. At the root of this situation is the low rate of participation of older patients in clinical trials, often due to age limits for inclusion, and limitations on the participation of persons with significant comorbidities or organ dysfunction. Although this has begun to change in recent years, most agents currently in use have not been tested in a substantial number of older patients. This includes the targeted agents that have, in the last fifteen years, changed the prognosis of patients with early and advanced breast cancer. Most data guiding the use of targeted agents in older patients come from sub-analysis of larger trials or small retrospective cohort studies. The goal of this review is to go over the available evidence regarding the efficacy and safety of targeted agents approved for use in breast cancer (trastuzumab, lapatinib, T-DM1, pertuzumab, neratinib, palbociclib, bevacizumab, ribociclib, abemaciclib, everolimus, olaparib, talazoparib), and place their side effects into an older-specific context in order to help medical oncologists when making treatment decisions and managing older patients with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
83. Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule.
- Author
-
Hu, Qida, Wu, Wangteng, Wang, Meng, Shao, Shiyi, Jin, Piaopiao, Chen, Qi, Bai, Hongzhen, Zhao, Xinyu, Huang, Junming, Wang, Jianwei, Tang, Guping, and Liang, Tingbo
- Subjects
- *
CANCER cell growth , *EXPOSURE dose , *DRUG resistance , *POLYAMIDOAMINE dendrimers - Abstract
Malignancies treated by insoluble targeted agents show low dose exposure and therapeutic responses, therefore easily develop drug resistance. Nanoparticle-modified drugs might disrupt chemoresistance by increasing dose exposure and altering resistance pathways, as administrated via the intravenous route to maximize efficacy. Herein, we proposed a self-assembled nanocapsulation strategy to construct a nanocomplex with multiarm polymer and novel dendrimer series (MAP-mG3) for encapsulating insoluble inhibitors by nucleotide lock. MAP-mG3 delivering the mammalian target of rapamycin (mTOR) inhibitor OSI-027 (MAP-mG3/OSI-027) showed higher loading capacity, enhanced solubility, controlled release, and increased intracellular tumoral accumulation. MAP-mG3/OSI-027, more efficiently than the free targeted agents, attenuated mTOR phosphorylation and inhibited growth of pancreatic cancer cells. In addition, MAP-mG3/OSI-027 reverted chemoresistance to OSI-027 in drug resistance pancreatic cancer by increasing intracellular dose exposure, as well as regulating ABCB1 expression and compensatory pathways. The optimized nanocapsulation design provides an effective strategy to engineer and reactivate insoluble targeted agents for chemoresistant applications. Unlabelled Image [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
84. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
- Author
-
Hauser, Haley, Gerson, Daniela Shveid, Reidy-Lagunes, Diane, and Raj, Nitya
- Abstract
Opinion Statement: Over the years, there have been significant advances in systemic treatments for metastatic pancreatic neuroendocrine tumors (panNETs). Despite these advancements, uncertainty remains regarding how to best sequence available therapies. For well-differentiated and metastatic panNETs that are somatostatin receptor (SSTR) avid on functional imaging, first-line therapy typically consists of somatostatin analogs (SSAs), given their favorable toxicity profile and overall low burden for patients. When progression of disease is observed on an SSA, multiple treatment options are available, including the targeted agents everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), as well as chemotherapy, with the latter often preferred for those panNETs of heavy tumor burden, higher grade, and/or more aggressive behavior clinically and/or radiographically. Here, we review panNET classification, currently available systemic treatments, therapy sequencing, and areas of active investigation to further our treatments for the disease. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
85. Meta‐Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.
- Author
-
Capdevila, Jaume, Hernando, Jorge, Perez‐Hoyos, Santiago, Roman‐Gonzalez, Alejandro, and Grande, Enrique
- Subjects
ANTINEOPLASTIC agents ,COMPARATIVE studies ,META-analysis ,METASTASIS ,NEUROENDOCRINE tumors ,OCTREOTIDE acetate ,PLACEBOS ,SURVIVAL analysis (Biometry) ,TIME ,EARLY medical intervention ,DESCRIPTIVE statistics ,EVEROLIMUS - Abstract
Background: Most guidelines still recommend active surveillance for patients with asymptomatic, unresectable neuroendocrine tumors (NETs). However, recent findings from several randomized placebo‐controlled trials suggest that most patients would benefit from active treatment. We conducted a meta‐analysis of pooled outcomes from clinical trials in which an active treatment arm was compared with placebo to determine whether active treatment provides a survival advantage. Materials and Methods: This meta‐analysis evaluated six trials that compared a medication with placebo in patients with an asymptomatic, metastatic NET. The trials were heterogenous with regard to the active medication (octreotide, lanreotide, sunitinib, everolimus, Lu‐Dotatate) and tumor localizations (gastrointestinal, pancreas, lung). Overall survival (OS) and progression‐free survival (PFS) for the placebo and active treatment arms were obtained from individual trial data and combined to obtain pooled outcomes. Results: The individual trials all reported significantly better PFS outcomes for active treatment. The pooled data confirmed this advantage. At months 3, 6, 12, 18, and 24, pooled PFS rates for the placebo and treatment arms, respectively, were 92.9% versus 96.9%; 54.3% versus 83.7%; 35.5% versus 68.5%; 25.1% versus 54.7%; and 17.7% versus 61.0%. OS was also higher in the active treatment groups. At months 6, 12, 24, 36, 48, and 60, OS rates (placebo vs. active treatment), respectively, were 88.1% versus 93.4%; 84.1% versus 86.2%; 67.4% versus 76%; 56.6% versus 64.4%; 49.9% versus 61.0%; and 41.7% versus 45.9%. Conclusion: This meta‐analysis confirms findings from recent clinical trials indicating that active treatment yields better survival outcomes than placebo. Importantly, these findings were obtained across a wide range of patient profiles and diverse medical treatments for metastatic NETs. Given the lack of reliable prognostic factors to determine a priori which patients are unlikely to benefit from active treatment, these findings support early treatment in most patients. Implications for Practice: Although most guidelines still recommend active surveillance for patients diagnosed with metastatic neuroendocrine tumors, the results of this meta‐analysis, together with recent data from key clinical trials, suggest that most patients could benefit from upfront active treatment. However, more data are needed to confirm this. Neuroendocrine tumors (NETs) are slow‐growing and often asymptomatic and the optimal upfront management approach is controversial. Despite the lack of evidence‐based data, the watch‐and‐wait strategy is still included in clinical guidelines. The present article reports the results of a meta‐analysis of phase III clinical trials that have compared active treatment to placebo in patients with metastatic NETs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
86. Future Directions and Clinical Trials in Penile Cancer
- Author
-
Sharma, Pranav, Protzel, Chris, Spiess, Philippe E., Muneer, Asif, editor, and Horenblas, Simon, editor
- Published
- 2016
- Full Text
- View/download PDF
87. Types of Radiation-Related Skin Reactions
- Author
-
Fowble, Barbara, Yom, Sue S., Yuen, Florence, Fowble, Barbara, editor, Yom, Sue S., editor, Yuen, Florence, editor, and Arron, Sarah, editor
- Published
- 2016
- Full Text
- View/download PDF
88. Scope of the Problem
- Author
-
Fowble, Barbara, Fowble, Barbara, editor, Yom, Sue S., editor, Yuen, Florence, editor, and Arron, Sarah, editor
- Published
- 2016
- Full Text
- View/download PDF
89. Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia
- Author
-
Elisa Albi, Antonella Capasso, Luana Schiattone, Paolo Ghia, Lydia Scarfò, Albi, E., Capasso, A., Schiattone, L., Ghia, P., and Scarfo, L.
- Subjects
Adult ,IGHV ,Cancer Research ,Mutation ,Quality of Life ,Humans ,Receptors, Antigen, B-Cell ,Chronic lymphocytic leukemia ,Antineoplastic Agents ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Targeted agents ,TP53 disruption - Abstract
With its heterogeneous biological features and clinical course, chronic lymphocytic leukemia (CLL), the most frequent adult leukemia in the Western world, is a paradigmatic condition requiring a tailored approach and a precise knowledge of the biology behind each individual patient. This personalized management is becoming even more crucial, since, after decades of preclinical work unravelling the key role of the B-cell receptor (BcR) signalling pathways and the anti-apoptotic mechanisms in CLL cell survival and proliferation, we have now BcR and BCL2 inhibitors available in clinical practice. Thanks to this, we are now able to exploit specific biomarkers to tailor our treatment strategies and improve long-term disease control, patient outcome and quality of life. That notwithstanding, as the disease itself remains incurable, novel challenges and unmet clinical needs have risen from the introduction of novel targeted agents, including mechanisms of resistance at both genetic and epigenetic levels. In this review, we summarize the currently established predictive biomarkers (i.e. IGHV mutation status and TP53 gene disruption) that should be applied in clinical practice to inform treatment decision in 2021 but also discuss the most promising prognostic biomarkers (B-cell receptor stereotypy, complex karyotype, somatic gene mutations, measurable residual disease - MRD) that might become key to define the management of our patients in a near future.
- Published
- 2022
90. Biomarkers in Metastatic Colorectal Cancer : Predicting Prognosis and Therapeutic Response
- Author
-
Diakos, Connie I., Charles, Kellie A., Chua, Wei, Howell, Viive M., Clarke, Stephen J., Preedy, Victor R., Series editor, and Patel, Vinood B., editor
- Published
- 2015
- Full Text
- View/download PDF
91. Emerging therapeutic agents for lung cancer
- Author
-
Bhagirathbhai Dholaria, William Hammond, Amanda Shreders, and Yanyan Lou
- Subjects
Lung cancer ,Targeted agents ,Immunotherapy ,Phase I/II clinical trial ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.
- Published
- 2016
- Full Text
- View/download PDF
92. Management of AML Beyond '3 + 7' in 2019
- Author
-
Jonathan Canaani
- Subjects
Acute myeloid leukemia ,Targeted agents ,FLT3 ,bcl-2 ,IDH1 ,IDH2 ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis. Whereas standard treatment for AML until recently consisted of a classic chemotherapy backbone, the incorporation of novel agents targeting pathogenic mutations, myeloid surface markers, and apoptosis-related proteins may become a reality in the next few years. In this review, we outline the therapeutic landscape of recently approved novel agents for AML, including FLT3 inhibitors, isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors, Bcl-2 antagonists, hedgehog signaling inhibitors, and immunotherapy-based approaches. Some of the future challenges in the field would be to delineate which specific patient subsets derive the most clinical benefit from a given novel agent and, furthermore, which drug combinations will yield the maximal antileukemia effect without increased toxicity. To this end, it is expected that advances in genomic and epigenomic classification of AML will facilitate a rational and optimal choice of these novel agents for AML patients.
- Published
- 2019
- Full Text
- View/download PDF
93. Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies.
- Author
-
Tarpgaard LS, Winther SB, and Pfeiffer P
- Abstract
Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).
- Published
- 2023
- Full Text
- View/download PDF
94. Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
- Author
-
Venus Sosa Iglesias, Jan Theys, Arjan J. Groot, Lydie M. O. Barbeau, Alyssa Lemmens, Ala Yaromina, Mario Losen, Ruud Houben, Ludwig Dubois, and Marc Vooijs
- Subjects
non-small cell lung cancer ,chemotherapy ,targeted agents ,radiation ,NOTCH/gamma-secretase inhibitor ,multicellular tumor spheroids ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Lung cancer is the leading cause of cancer death worldwide. More effective treatments are needed to increase durable responses and prolong patient survival. Standard of care treatment for patients with non-operable stage III-IV NSCLC is concurrent chemotherapy and radiation. An activated NOTCH signaling pathway is associated with poor outcome and treatment resistance in non-small cell lung cancer (NSCLC). NOTCH/γ-secretase inhibitors have been effective in controlling tumor growth in preclinical models but the therapeutic benefit of these inhibitors as monotherapy in patients has been limited so far. Because NOTCH signaling has been implicated in treatment resistance, we hypothesized that by combining NOTCH inhibitors with chemotherapy and radiotherapy this could result in an increased therapeutic effect. A direct comparison of the effects of NOTCH inhibition when combined with current treatment combinations for NSCLC is lacking.Methods: Using monolayer growth assays, we screened 101 FDA-approved drugs from the Cancer Therapy Evaluation Program alone, or combined with radiation, in the H1299 and H460 NSCLC cell lines to identify potent treatment interactions. Subsequently, using multicellular three-dimensional tumor spheroid assays, we tested a selection of drugs used in clinical practice for NSCLC patients, and combined these with a small molecule inhibitor, currently being tested in clinical trials, of the NOTCH pathway (BMS-906024) alone, or in combination with radiation, and measured specific spheroid growth delay (SSGD). Statistical significance was determined by one-way ANOVA with post-hoc Bonferroni correction, and synergism was assessed using two-way ANOVA.Results: Monolayer assays in H1299 and H460 suggest that 21 vs. 5% were synergistic, and 17 vs. 11% were additive chemoradiation interactions, respectively. In H1299 tumor spheroids, significant SSGD was obtained for cisplatin, etoposide, and crizotinib, which increased significantly after the addition of the NOTCH inhibitor BMS-906024 (but not for paclitaxel and pemetrexed), and especially in triple combination with radiation. Synergistic interactions were observed when BMS-906024 was combined with chemoradiation (cisplatin, paclitaxel, docetaxel, and crizotinib). Similar results were observed for H460 spheroids using paclitaxel or crizotinib in dual combination treatment with NOTCH inhibition and triple with radiation.Conclusions: Our findings point to novel synergistic combinations of NOTCH inhibition and chemoradiation that should be tested in NSCLC in vivo models for their ability to achieve an improved therapeutic ratio.
- Published
- 2018
- Full Text
- View/download PDF
95. New Anticancer Agents in Neuroendocrine Tumors
- Author
-
Benavent, Marta, Sanchez-Gastaldo, Amparo, Garcia-Carbonero, Rocio, Raymond, Eric, editor, Faivre, Sandrine, editor, and Ruszniewski, Philippe, editor
- Published
- 2014
- Full Text
- View/download PDF
96. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non‐small‐cell lung cancer: A network meta‐analysis of nine eligible randomized controlled trials involving 5,059 patients.
- Author
-
Liu, Gui‐Feng, Li, Xue‐Feng, Yu, Shao‐Nan, Miao, Ying‐Ying, and Zhang, Shu‐Hua
- Subjects
- *
LUNG cancer treatment , *TREATMENT effectiveness , *PROGRESSION-free survival , *CELL-mediated cytotoxicity , *QUALITY of life , *RANDOMIZED controlled trials - Abstract
Recently, targeted agents were reported to improve overall survival, progression‐free survival (PFS), response rate, and quality of life compared with cytotoxic chemotherapies, which provides hope for the treatment of non‐small‐cell lung cancer (NSCLC). The network meta‐analysis is applied to compare the efficacies and adverse events of five targeted agents (erlotinib, gefitinib, vandetanib, dacomitinib, and icotinib) for advanced or metastatic NSCLC. Nine eligible randomized controlled trials from PubMed and Cochrane Library database were included. Weighted mean difference, odds ratio, and surface under the cumulative ranking curve (SUCRA) values were evaluated for the efficacy and adverse events of the five targeted agents in the treatment of NSCLC. With regard to efficacy, the overall response rate (ORR) of advanced or metastatic NSCLC patients treated with gefitinib was relatively higher than those treated with placebo. Compared with patients treated with placebo, the disease control rate (DCR) of patients treated with erlotinib and with gefitinib was relatively higher. Furthermore, in terms of PFS and DCR, the SUCRA value of icotinib was the highest among the five targeted drugs. With regard to ORR, the SUCRA value of gefitinib was the highest among the five targeted drugs. In terms of fatigue, rash, and cough, erlotinib had the lowest SUCRA value, whereas vandetanib exhibited the lowest SUCRA value in terms of diarrhea. Our study suggests that the efficacies of gefitinib and icotinib for advanced or metastatic NSCLC were comparatively better, whereas the toxicities of erlotinib and vandetanib were relatively greater. The efficacies of gefitinib and icotinib for advanced or metastatic NSCLC were comparatively better, whereas the toxicities of erlotinib and vandetanib were relatively greater. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
97. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
- Author
-
Cloyd, Jordan M., Konda, Bhavana, Shah, Manisha H., and Pawlik, Timothy M.
- Subjects
NEUROENDOCRINE tumors ,SOMATOSTATIN ,RADIOTHERAPY ,CANCER treatment ,CLINICAL trials - Abstract
Introduction: Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are unique and complex neoplasms, exhibiting a wide spectrum of diverse clinical behaviors. The contemporary management of well-differentiated GEP-NETs is marked by the availability of a wide range of targeted therapies. Areas Covered: For patients with localized or oligometastatic disease, surgical resection remains the preferred approach and is associated with excellent long-term outcomes. For patients with unresectable but isolated liver metastases, multiple liver-directed therapies, including hepatic arterial based therapies and ablative techniques, exist. For patients with metastatic and progressive disease, a number of systemic therapies exist: molecular targeted agents, peptide receptor radionuclide therapy (PRRT), and systemic chemotherapy. Furthermore, somatostatin analogs (SSA) are an important component of therapy, both effectively controlling symptoms of hormonal overproduction and contributing to slowing tumor progression. Expert Opinion: In the near future, advances in our understanding of tumor biology, genetics, immunology, nanotechnology, and radiation pharmacology should only continue to expand the availability of targeted therapies, improving the outcomes of patients with GEP-NETs. We herein review the management of advanced well-differentiated GEP-NETS with a particular emphasis on the role of targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
98. FLT3 inhibitors in acute myeloid leukemia: Current and future.
- Author
-
Thomas, Christan M. and Campbell, Peter
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *SORAFENIB , *CELL proliferation , *CANCER chemotherapy , *CANCER relapse , *DRUG toxicity , *HEMATOPOIETIC stem cells , *GENETIC mutation , *SURVIVAL , *TUMOR classification , *DRUG approval , *DISEASE remission , *ACUTE myeloid leukemia , *GENETICS , *PROGNOSIS , *THERAPEUTICS - Abstract
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is responsible for the proliferation and survival of hematopoietic stem cells in acute myeloid leukemia. Although patients with FLT3 mutations have similar rates of remission following induction chemotherapy, relapse rates are significantly higher and patients with FLT3 mutations have significantly worse outcomes for overall survival and disease-free survival. Early FLT3 inhibitors, such as sorafenib, were non-selective and inhibited several tyrosine kinase receptors resulting in significant toxicity. The treatment of FLT3-positive acute myeloid leukemia has advanced recently with the development of a several FLT3-targeting agents that are either approved or in development. Midostaurin represents the first FDA-approved treatment targeted against FLT3, and there are several promising agents currently undergoing clinical trials. Although certain mutations confer resistance to earlier generation FLT3-targeted tyrosine kinase inhibitors, newer agents show activity in the presence of these mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
99. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018).
- Author
-
Gómez-España, M. A., Gallego, J., González-Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliu, J., and Vera, R.
- Abstract
Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. The optimal treatment strategy for patients with metastatic CRC should be discussed in a multidisciplinary expert team to select the most appropriate treatment, and integrate systemic treatment and other options such as surgery and ablative techniques depending on the characteristics of the tumour, the patient and the location of the disease and metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
100. Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells.
- Author
-
Sosa Iglesias, Venus, Theys, Jan, Groot, Arjan J., Barbeau, Lydie M. O., Lemmens, Alyssa, Yaromina, Ala, Losen, Mario, Houben, Ruud, Dubois, Ludwig, and Vooijs, Marc
- Abstract
Background: Lung cancer is the leading cause of cancer death worldwide. More effective treatments are needed to increase durable responses and prolong patient survival. Standard of care treatment for patients with non-operable stage III-IV NSCLC is concurrent chemotherapy and radiation. An activated NOTCH signaling pathway is associated with poor outcome and treatment resistance in non-small cell lung cancer (NSCLC). NOTCH/γ-secretase inhibitors have been effective in controlling tumor growth in preclinical models but the therapeutic benefit of these inhibitors as monotherapy in patients has been limited so far. Because NOTCH signaling has been implicated in treatment resistance, we hypothesized that by combining NOTCH inhibitors with chemotherapy and radiotherapy this could result in an increased therapeutic effect. A direct comparison of the effects of NOTCH inhibition when combined with current treatment combinations for NSCLC is lacking. Methods: Using monolayer growth assays, we screened 101 FDA-approved drugs from the Cancer Therapy Evaluation Program alone, or combined with radiation, in the H1299 and H460 NSCLC cell lines to identify potent treatment interactions. Subsequently, using multicellular three-dimensional tumor spheroid assays, we tested a selection of drugs used in clinical practice for NSCLC patients, and combined these with a small molecule inhibitor, currently being tested in clinical trials, of the NOTCH pathway (BMS-906024) alone, or in combination with radiation, and measured specific spheroid growth delay (SSGD). Statistical significance was determined by one-way ANOVA with post-hoc Bonferroni correction, and synergism was assessed using two-way ANOVA. Results: Monolayer assays in H1299 and H460 suggest that 21 vs. 5% were synergistic, and 17 vs. 11% were additive chemoradiation interactions, respectively. In H1299 tumor spheroids, significant SSGD was obtained for cisplatin, etoposide, and crizotinib, which increased significantly after the addition of the NOTCH inhibitor BMS-906024 (but not for paclitaxel and pemetrexed), and especially in triple combination with radiation. Synergistic interactions were observed when BMS-906024 was combined with chemoradiation (cisplatin, paclitaxel, docetaxel, and crizotinib). Similar results were observed for H460 spheroids using paclitaxel or crizotinib in dual combination treatment with NOTCH inhibition and triple with radiation. Conclusions: Our findings point to novel synergistic combinations of NOTCH inhibition and chemoradiation that should be tested in NSCLC in vivo models for their ability to achieve an improved therapeutic ratio. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.